The interplay between mTORC1/2 signaling on the DDR and the sensitivity of breast cancer cell lines with impaired BRCA1 status to mTORC1/2 inhibition also suggests the potential for tailored treatment based on the patient’s underlying genetics. Here, BRCA1 is linked to breast carcinoma.